Comparative Pharmacology
Head-to-head clinical analysis: SPRX 105 versus SPRX 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SPRX 105 versus SPRX 3.
SPRX-105 vs SPRX-3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SPRX-105 is a dual dopamine D2 and serotonin 5-HT1A receptor partial agonist, functioning as a postsynaptic antagonist and presynaptic agonist at D2 receptors, and as a partial agonist at 5-HT1A receptors, modulating neurotransmitter release.
Selective sigma-2 receptor ligand; induces mitochondrial dysfunction and endoplasmic reticulum stress leading to apoptosis in cancer cells. Also modulates autophagy.
SPRX-105 is administered orally at a dose of 50 mg once daily.
Not established; investigational drug. No approved standard adult dose available.
None Documented
None Documented
12-15 hours in healthy adults; extended to 24-30 hours in renal impairment.
Terminal elimination half-life: 12 ± 3 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min).
Primarily renal (70-80% unchanged) with 15-20% biliary/fecal elimination.
Primarily renal (70% unchanged, 15% as glucuronide conjugate); biliary/fecal (10%); other (5%).
Category C
Category C
Unknown
Unknown